Breckenridge Introduces Everolimus Tablets, 1mg
Breckenridge Pharmaceutical, Inc. has announced the launch of Everolimus Tablets, 1mg, a generic equivalent of Novartis’ Zortress. The product is an important addition to breast cancer and organ transplantation treatments, particularly effective for patients undergoing kidney and liver transplants.
About Everolimus
Everolimus is categorized as an mTOR inhibitor immunosuppressant. It plays a crucial role in preventing organ rejection for patients receiving transplants, particularly in complex procedures such as kidney and liver transplants. With its efficacy in the prophylaxis of organ rejection, Everolimus stands as a significant advancement in transplantation therapy.
Availability and Configuration
This new formulation of Everolimus Tablets will debut in both bottles and blister card configurations, enhancing accessibility for patients. Breckenridge previously launched Everolimus in 0.25mg, 0.5mg, and 0.75mg dosages, ensuring that patients have a range of options to fit their individual medical needs. The blister packs were introduced in mid-2021, followed by bottled versions in mid-2023.
Company Commitment
The company is dedicated to addressing the healthcare needs of various patient populations by offering these formulations at affordable prices. Brian Guy, President and CCO of Breckenridge Pharmaceutical, emphasized the company’s commitment to developing innovative therapies that provide accessible and effective treatment options.
Partnership with Natco Pharma
The development of Everolimus Tablets involved a collaborative effort with Natco Pharma Limited, an esteemed pharmaceutical manufacturer based in India. This partnership enriches Breckenridge's portfolio while ensuring that quality and effectiveness remain at the forefront of their offerings.
About Breckenridge Pharmaceutical, Inc.
Founded with the aim of delivering high-quality generic pharmaceuticals, Breckenridge Pharmaceutical, Inc. acts as the U.S. arm of Towa International. With a strong commitment to patient care and public health, Breckenridge partners with reputable manufacturers to provide cost-effective medications. Their strategy highlights not just customer service but also on-time delivery and reliable supply, marking them as a trusted provider in the pharmaceutical landscape.
Contact Information
For more information regarding Breckenridge Pharmaceutical and their offering of Everolimus Tablets, stakeholders and the public can explore more through their channels. While the email contact option is not valid here, interested parties can reach out through official business inquiries.
Frequently Asked Questions
What are Everolimus Tablets used for?
Everolimus Tablets are primarily used to prevent organ rejection in adult patients undergoing kidney and liver transplants.
How is Everolimus administered?
Everolimus is typically available in tablet form and can be obtained through retail and mail order pharmacies.
What strengths of Everolimus does Breckenridge offer?
Breckenridge offers Everolimus Tablets in various strengths: 0.25mg, 0.5mg, 0.75mg, and now 1mg.
Who developed Everolimus Tablets for Breckenridge?
The tablets were developed in partnership with Natco Pharma Limited from India, bringing robust pharmaceutical expertise to the collaboration.
Where can I find more information about Breckenridge?
For comprehensive information on Breckenridge Pharmaceutical, visit their website to explore their products and services.
